Meningioma Clinical Trial
Official title:
Pilot/Phase I Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior
Primary Objective: I. To assess the feasibility of hyperpolarized 13C MR imaging as a new and unique tool in the characterization of aggressive tumor behavior in participants with meningioma. Secondary Objectives: I. To define the most appropriate parameters for obtaining hyperpolarized 13C data from meningioma patients with a run-in study to optimize spatial and temporal resolution and coverage by detecting signal amplitudes and time dynamics. II. To measure tumor pyruvate-to-lactate, pyruvate-to-alanine, and pyruvate-to-bicarbonate conversion by 13C pyruvate MR imaging in participants with meningioma planning to undergo surgical resection within 4 weeks, using parameters. Outline: Participants will receive a single imaging procedure using HP 13C pyruvate. Participants will then be followed-up for 30 days after completion of the study or until voluntary withdrawal or death. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04081701 -
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
|
Phase 4 | |
| Recruiting |
NCT03631953 -
Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas
|
Phase 1 | |
| Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
| Recruiting |
NCT04367779 -
Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
|
||
| Withdrawn |
NCT00985036 -
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
|
N/A | |
| Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
| Completed |
NCT01811524 -
The Etiology and Progression of Brain Tumors
|
N/A | |
| Completed |
NCT03648034 -
Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality
|
N/A | |
| Recruiting |
NCT06036706 -
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:
|
N/A | |
| Not yet recruiting |
NCT04386642 -
Tranexamic Acid Reduce Blood Loss in Meningioma Resection
|
Phase 4 | |
| Active, not recruiting |
NCT04595786 -
The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection
|
N/A | |
| Completed |
NCT04305470 -
Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
|
Phase 3 | |
| Completed |
NCT01967823 -
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02978677 -
Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas
|
N/A | |
| Active, not recruiting |
NCT02933736 -
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
|
Early Phase 1 | |
| Completed |
NCT02267928 -
Information Presentation Formats
|
N/A | |
| Completed |
NCT00589784 -
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
|
Phase 2 | |
| Active, not recruiting |
NCT03071874 -
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
|
Phase 2 | |
| Recruiting |
NCT05416567 -
Embolization for Meningioma
|
N/A | |
| Not yet recruiting |
NCT06126588 -
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
|
Phase 2 |